WO2012159593A3 - Formulation orale combinée à libération contrôlée d'acide acétylsalicylique et procédé pour la préparation - Google Patents

Formulation orale combinée à libération contrôlée d'acide acétylsalicylique et procédé pour la préparation Download PDF

Info

Publication number
WO2012159593A3
WO2012159593A3 PCT/CZ2012/000042 CZ2012000042W WO2012159593A3 WO 2012159593 A3 WO2012159593 A3 WO 2012159593A3 CZ 2012000042 W CZ2012000042 W CZ 2012000042W WO 2012159593 A3 WO2012159593 A3 WO 2012159593A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
controlled release
acetylsalicylic acid
combined oral
oral formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CZ2012/000042
Other languages
English (en)
Other versions
WO2012159593A2 (fr
WO2012159593A9 (fr
Inventor
OIga SAKOVA
Beata Vladovicova
Anna KABZANOVA
Viera Kormanova
Stefan ZORICAK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Zentiva KS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva KS filed Critical Zentiva KS
Priority to ROA201300838A priority Critical patent/RO130316A2/ro
Priority to UAA201315213A priority patent/UA111743C2/uk
Publication of WO2012159593A2 publication Critical patent/WO2012159593A2/fr
Publication of WO2012159593A3 publication Critical patent/WO2012159593A3/fr
Publication of WO2012159593A9 publication Critical patent/WO2012159593A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention a pour objet une formulation pharmaceutique solide orale combinée à libération contrôlée d'acide acétylsalicylique, qui comprend au moins un autre principe actif choisi dans le groupe des analgésiques non narcotiques et/ou des agents psychotropes naturels, et de l'acide stéarique et de l'amidon en tant qu'excipients dans un rapport spécifique, et un procédé pour sa préparation.
PCT/CZ2012/000042 2011-05-25 2012-05-24 Formulation orale combinée à libération contrôlée d'acide acétylsalicylique et procédé pour la préparation Ceased WO2012159593A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ROA201300838A RO130316A2 (ro) 2011-05-25 2012-05-24 Formulare orală combinată cu eliberare controlată a acidului acetilsalicilic şi procedeu pentru prepararea acesteia
UAA201315213A UA111743C2 (uk) 2011-05-25 2012-05-24 Комбінована пероральна композиція з контрольованим вивільненням ацетилсаліцилової кислоти і спосіб її одержання

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SK5028-2011A SK50282011A3 (sk) 2011-05-25 2011-05-25 Controlled acetylsalicylic acid release combined peroral preparation and method for the production thereof
SKPP5028-2011 2011-05-25

Publications (3)

Publication Number Publication Date
WO2012159593A2 WO2012159593A2 (fr) 2012-11-29
WO2012159593A3 true WO2012159593A3 (fr) 2013-01-17
WO2012159593A9 WO2012159593A9 (fr) 2013-03-07

Family

ID=46513601

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ2012/000042 Ceased WO2012159593A2 (fr) 2011-05-25 2012-05-24 Formulation orale combinée à libération contrôlée d'acide acétylsalicylique et procédé pour la préparation

Country Status (5)

Country Link
CZ (1) CZ20131028A3 (fr)
RO (1) RO130316A2 (fr)
SK (1) SK50282011A3 (fr)
UA (1) UA111743C2 (fr)
WO (1) WO2012159593A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1117646A (en) * 1964-10-16 1968-06-19 Eastman Kodak Co 3-azabicyclo[3.2.2] nonane derivatives
US4505862A (en) * 1981-04-14 1985-03-19 Bristol-Myers Company Diphenydramine dihydrogencitrate
WO2009022821A2 (fr) * 2007-08-13 2009-02-19 Hanall Pharmaceutical Company. Ltd Préparation combinée contenant un inhibiteur de hmg-coa reductase et aspirine et son procédé d'élaboration
WO2010081722A2 (fr) * 2009-01-16 2010-07-22 Add Technologies Ltd. Comprimés à désintégration orale pour traiter la douleur

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT72408A (en) 1993-09-10 1996-04-29 Egyt Gyogyszervegyeszeti Gyar Process for producing tablets containing acetyl-salicylic acid

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1117646A (en) * 1964-10-16 1968-06-19 Eastman Kodak Co 3-azabicyclo[3.2.2] nonane derivatives
US4505862A (en) * 1981-04-14 1985-03-19 Bristol-Myers Company Diphenydramine dihydrogencitrate
WO2009022821A2 (fr) * 2007-08-13 2009-02-19 Hanall Pharmaceutical Company. Ltd Préparation combinée contenant un inhibiteur de hmg-coa reductase et aspirine et son procédé d'élaboration
WO2010081722A2 (fr) * 2009-01-16 2010-07-22 Add Technologies Ltd. Comprimés à désintégration orale pour traiter la douleur

Also Published As

Publication number Publication date
CZ20131028A3 (cs) 2014-01-29
WO2012159593A2 (fr) 2012-11-29
UA111743C2 (uk) 2016-06-10
SK50282011A3 (sk) 2013-02-04
RO130316A2 (ro) 2015-06-30
WO2012159593A9 (fr) 2013-03-07

Similar Documents

Publication Publication Date Title
WO2012021715A3 (fr) Formulations stables de linaclotide
WO2008146178A3 (fr) Nouvelle forme posologique de comprimé
CL2013001586A1 (es) Composicion microgranular de rapida dispersion que comprende al menos un alcohol de azucar, un sacarido, o una mezcla de estos, al menos un super disgregante y al menos un aditivo multifuncion; comprimido de desintegracion oral que comprende la composicion microgranular y al menos un principio activo; y metodos de fabricacion.
MX2013014788A (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
WO2009117130A3 (fr) Formulation à libération prolongée contenant une cire
WO2009063222A3 (fr) Compositions solides
WO2012022919A3 (fr) Formulations à base de nalbuphine et leurs utilisations
WO2010021607A3 (fr) Préparation pharmaceutique
MX2011007817A (es) Formulacion farmaceutica o alimenticia de liberacion controlada y proceso para su preparacion.
HK1213779A1 (zh) 用於立即和延长释放的组合物
IL195931A0 (en) Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and methods for its production
WO2011104652A3 (fr) Compositions vétérinaires
UA103025C2 (ru) Твердая композиция лекарственного средства замедленного высвобождения
WO2011108826A3 (fr) Formulation complexe pour administration orale comprenant une formulation probiotique et un agoniste du récepteur 5-ht4, et procédé de préparation associé
WO2010009140A3 (fr) Procédés, systèmes et dispositifs destinés à l'administration de dioxyde de chlore
WO2012074830A3 (fr) Formulation d'acide tranexamique à libération modifiée
HK1208222A1 (en) Modified release formulations for oprozomib
WO2011069076A3 (fr) Formulation de donépézil à libération prolongée
WO2011002422A3 (fr) Formulation pharmaceutique améliorant la solubilité
MD4563B1 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
WO2012085284A3 (fr) Formulations pharmaceutiques à charge médicamenteuse élevée comprenant de la dronédarone et des sels pharmaceutiquement acceptables de celles-ci
WO2009149058A3 (fr) Formulations de niacine à libération modifiée
TR201803451T4 (tr) Olmesartan formülasyonlari.
WO2012159593A9 (fr) Formulation orale combinée à libération contrôlée d'acide acétylsalicylique et procédé pour la préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12735186

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013 201300838

Country of ref document: RO

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: PV2013-1028

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: A201315213

Country of ref document: UA

122 Ep: pct application non-entry in european phase

Ref document number: 12735186

Country of ref document: EP

Kind code of ref document: A2